WHO ICTRP trial
An Exploratory Clinical Study of Lenvatinib Combined with Iparomlimab and…
ChiCTR2500115667 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2500115667 |
|---|---|
| Public title | An Exploratory Clinical Study of Lenvatinib Combined with Iparomlimab and Tuvonralimab and TACE for the Conversion Therapy of Potentially Resectable Hepatocellular Carcinoma |
| Scientific title | An Exploratory Clinical Study of Lenvatinib Combined with Iparomlimab and Tuvonralimab and TACE for the Conversion Therapy of Potentially Resectable Hepatocellular Carcinoma |
| Primary sponsor | The First Affiliated Hospital of Anhui Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | HCC |
| Interventions | experimental group:Lenvimab + Iparomlimab and Tuvonralimab + TACE |
| Registration date | Dec 30, 2025 |
| Target size | experimental group:44 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: